Ofatumumab in relapsing remitting multiple sclerosis (RRMS) in the first 100 patients in Glasgow

<h3></h3> Ofatumumab is an anti-CD20 monoclonal antibody approved in 2021 for the treatment of RRMS. It is considered to be a highly effective disease modifying therapy (DMT) which is self-administered by subcutaneous monthly injections. We evaluated the efficacy and safety of ofatumumab in the first 100 patients treated in the West of Scotland. Patients were predominantly female (72%) with median age of 39 years (range 18–66). Most patients (71%) were escalated to ofatumumab from another DMT, the rest being DMT-naive. Among patients with previous DMT use (n=71), most had been treated with dimethyl fumarate (n=20, 28%). The most common reason for DMT switch was due to clinical and/or radiological breakthrough disease (76%, n=54). The median duration of ofatumumab treatment was 1 year (range 0.5–2.2). Five patients (5%) had relapses and/or new MRI lesions ≥6months after starting ofatumumab with only 1 patient requiring a change in treatment so far. In this group, mean duration of treatment was 1 year and ofatumumab was most commonly used as a second-line DMT (4/5). Side effects were reported in 31% of patients, with flu-like symptoms being the most common (64.5%). Infections were reported in almost half (46%) but only 1 patient discontinued due to recurrent infections.